At a glance
ClinicalIndex Comparison RecordN/ACompleted· 412 enrolled
Drug / intervention
SYNERGY Investigational Device +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
EVOLVE China: A Prospective, Multicenter Trial to Assess the Safety and Effectiveness of the SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System (SYNERGY Stent System) for the Treatment of Atherosclerotic Lesion(s)
In Brief
A clinical study evaluating SYNERGY Investigational Device and PE Plus Investigational Device for Coronary Artery Disease. Completed, enrolled 412 participants across 14 sites.
Detailed Summary
The purpose of this study is to assess the safety and effectiveness of the SYNERGY™ Coronary Stent System for the treatment of subjects with atherosclerotic lesion(s) ≤ 34 mm in length (by visual estimate) in native coronary arteries ≥2.25 mm to ≤4.0 mm in diameter (by visual estimate)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Artery Disease
CountriesChina
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartOct 2013
First PostedOct 2013
Primary CompletionJul 2014
Study CompletionDec 2020
TodayJul 2026
First PostedOct 21, 2013
Enrollment StartOct 1, 2013
Primary CompletionJul 1, 2014
Study CompletionDec 1, 2020
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 12.7 years ago
Interventions
SYNERGY Investigational Devicedevice
percutaneous coronary intervention
PE Plus Investigational Devicedevice
percutaneous coronary intervention